Loading...
Loading...
OCUL| Name | Value |
|---|---|
| Revenues | 13.4M |
| Cost of Revenue | 1.2M |
| Gross Profit | 12.2M |
| Operating Expense | 34.7M |
| Operating I/L | -22.5M |
| Other Income/Expense | -7.8M |
| Interest Income | 0.6M |
| Pretax | -30.3M |
| Income Tax Expense | 6.1M |
| Net Income/Loss | -36.4M |
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in developing and commercializing eye therapies using bioresorbable hydrogel-based formulation technology. The company's products include ReSure Sealant, used to prevent wound leaks in corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for treating post-surgical ocular inflammation, pain, and allergic conjunctivitis. Ocular Therapeutix is also advancing various products through clinical trials, such as OTX-TKI for wet age-related macular degeneration, OTX-TIC for open-angle glaucoma, and OTX-DED for dry eye disease. Additionally, the company has strategic collaborations with Regeneron Pharmaceuticals and AffaMed Therapeutics for product development and commercialization.
